Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis
Clinical Scorecard: Incidence of Arthritis in a Large Cohort of Pediatric Patients Diagnosed with Psoriasis
At a Glance
Category Detail
Condition Psoriatic Arthritis (PsA) in Pediatric Patients Key Mechanisms Development of JPsA associated with psoriasis severity, age at diagnosis, and uveitis. Target Population Pediatric patients with psoriasis (<18 years) and young adults (≥18 years) with a history of psoriasis. Care Setting Dermatology and Pediatric Rheumatology
Key Highlights
2% of children with psoriasis developed JPsA over a mean follow-up of 5 years. Older age at psoriasis diagnosis and presence of uveitis are identified risk factors for JPsA. JPsA accounts for approximately 8% of the Juvenile Idiopathic Arthritis population. Diagnosis of JPsA is challenging, especially in patients without psoriatic lesions. Guideline-Based Recommendations
Diagnosis
Children diagnosed with JPsA according to ILAR criteria. Young adults diagnosed with PsA according to CASPAR criteria. Management
Referral to a rheumatologist based on persistent joint complaints and elevated PEST scores. Monitoring & Follow-up
Regular follow-up visits to assess PASI score, BSA, BMI, and nail involvement. Risks
Risk factors for developing JPsA include older age at psoriasis diagnosis and uveitis. Patient & Prescribing Data
Pediatric patients with plaque psoriasis followed into young adulthood.
Data collected on treatment history and clinical characteristics at baseline and follow-up.
Clinical Best Practices
Early diagnosis of psoriatic arthritis is crucial for prevention. Consider referral to rheumatology for patients with persistent joint symptoms. Related Resources & Content
